Since there is no firm structural data on whether reported extragonadal FSHRs are variants of the canonical FSHR structure, particularly the FSHRs represented to be in bone, adipose tissue and malignant tumors (33, 177, 178), a more precise identification of such structural features might allow the design of highly specific therapeutic strategies, which block putative deleterious FSH effects on these particular tissues. This evidence concerns the gene BRD2 and cancer.